Short answer
Keros Therapeutics, Inc. (KROS) filed an 8-K current report with the SEC on July 22, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers). CFO Keith Regnante resigns August 3, 2026, voluntarily and without accounting or internal-control disagreements.
Keros Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- CFO Keith Regnante resigns August 3, 2026, voluntarily and without accounting or internal-control disagreements
- Corporate Controller Annita Tanini becomes interim principal financial and accounting officer August 4, 2026
- CFO search underway, creating near-term finance leadership uncertainty
- Tanini receives $302,300 base salary and 30% target annual cash bonus
- Tanini eligible for six months’ salary and COBRA coverage after qualifying termination
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Keros Therapeutics, Inc. 8-K filings
Get the next KROS 8-K as it lands
Follow KROS for push alerts, or ask the research agent what this filing means.